Ultrasound-guided five-point injection of botulinum toxin for patients with trapezius hypertrophy

J Orthop Surg Res. 2021 Oct 22;16(1):634. doi: 10.1186/s13018-021-02758-y.

Abstract

Objectives: Our study aimed to explore the clinical therapeutic effects of ultrasound-guided five-point injection of botulinum toxin type A for patients with trapezius hypertrophy.

Methods: Twenty female patients diagnosed with trapezius hypertrophy were enrolled in this study. The thicknesses of the trapezius muscle were measured by using the ultrasound scanner to locate the thickest point of trapezius, followed by labelling the other four points around the first point. Botulinum toxin type A was injected bilaterally (50 IU/side, 5 points/side) in the trapezius muscle of these patients. The surgery effects were evaluated by thicknesses of the trapezius muscle, intramuscular needle electromyographic and electroneurographic examinations, appearance changes and patients' satisfactions.

Results: Statistically significant differences in thicknesses of the trapezius muscle were observed at 4 weeks (p < 0.001), 12 weeks (p < 0.001), 20 weeks (p < 0.001), 28 weeks (p = 0.011), 36 weeks (p = 0.022), and 44 weeks (p = 0.032) after surgery. The latencies of trapezius muscle became longer at 12 weeks after surgery (left: 2.40 ms, right: 2.53 ms vs. left: 1.75 ms, right: 2.00 ms). Electroneurographic results showed amplitude reduction of compound muscle action potentials (CMAPs) at 12 weeks after surgery (left: 1.91 uV, right: 3.10 uV vs. left: 15.00 uV, right: 15.40 uV). Obvious appearance changes were revealed at 12 weeks after surgery. All of 80% patients were very satisfied, 15% patients were relatively satisfied, and 5% patients were not satisfied with the surgery.

Conclusion: Ultrasound-guided five-point injection of botulinum toxin type A might be effective for patients with trapezius hypertrophy.

Keywords: Botulinum toxin type A; Five-point; Trapezius hypertrophy.

MeSH terms

  • Botulinum Toxins, Type A* / administration & dosage
  • Female
  • Humans
  • Hypertrophy / diagnostic imaging
  • Hypertrophy / drug therapy
  • Neuromuscular Agents* / administration & dosage
  • Superficial Back Muscles* / diagnostic imaging
  • Ultrasonography
  • Ultrasonography, Interventional*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A